ClinicalTrials.gg
Active, not recruitingNCT02386670PACt-MDUpdated Apr 9, 2026

Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD)

An interventional study of tDCS + CR and sham tDCS + sham CR in Mild Cognitive Impairment, Major Depressive Disorder, Recurrent, In Remission and Major Depressive Disorder, Single Episode, in Full Remission, sponsored by Centre for Addiction and Mental Health. Active, not recruiting at 5 sites in Canada. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

This 7-year randomized controlled trial will compare the efficacy of non-invasive brain stimulation (trans-cranial Direct Current Stimulation - tDCS) combined with cognitive remediation (CR) versus sham ("placebo") tDCS combined with sham ("placebo") CR in slowing down cognitive decline and preventing Alzheimer's Dementia in older persons with mild cognitive impairment or major depressive disorder with or without mild cognitive impairment.

Read the detailed description

By the time Alzheimer's Dementia (AD) and related disorders (ADRD) are diagnosed the brain has sustained substantial insult that limits the efficacy of current treatments. Preventive interventions are urgently needed but prevention studies require large numbers of participants and long follow-up periods unless they can target a high-risk population.

The investigators propose to study the efficacy of a preventive intervention for AD in three high risk groups: (1) older persons with Mild Cognitive Impairment (MCI); (2) older persons with a major depressive disorder (MDD) without MCI; and (3) older persons with MDD and MCI.

MCI is considered a prodromal condition for dementia with a progression rate of about 1% per month. MDD has independently been identified as one of the most promising targets for AD prevention studies since, even after successful treatment of their depressive episode, older persons with remitted MDD develop MCI or dementia at a rate of 1-2% per month.

The investigators proposed intervention is a combination of cognitive remediation (CR) and non-invasive brain stimulation - transcranial Direct Current Stimulation (tDCS). Participants with MCI or MDD (with or without MCI) will be randomized to tDCS + CR or sham ("palcebo") tDCS + sham ("placebo") CR. Both CR and tDCS have been shown to induce neuroplasticity and improve cognition. The investigators hypothesize that their combination will enhance cognitive reserve and protect against cognitive decline and the onset of MCI in those with "normal" cognition or AD in those with MCI.

The investigators design is informed by their experience conducting randomized controlled trials (RCTs) in older participants with dementia, MCI, or MDD over more than two decades. In the investigators recent donepezil prevention trial, combining donepezil with standard antidepressant maintenance prevented cognitive decline and the incidence of dementia in participants who had had both MDD and MCI. Building on this prevention trial, the investigators conceptualize the proposed study as a high-risk, high-gain RCT aimed at enhancing cognitive reserve and preventing cognitive decline and dementia in a high risk population. If the investigators are successful in this high risk population, then tDCS + CR can be tested in, and extended to, the general population (i.e., for universal prevention) or other groups at high risk for AD (i.e., for selective or indicated prevention).

Five Toronto academic sites with a history of successful collaboration will consent up to a total of 500 participants meeting criteria for MCI (age 60 and older) or MDD (age 65 and older) to reach a target of 375 enrolled participants initiating the study intervention. Participants will be randomized to either: i) tDCS + CR or ii) sham tDCS + sham CR. They will first receive tDCS + CR (or sham + sham) 5 days a week for 8 weeks, followed by home-based CR (or sham) and booster sessions of tDCS + CR (or sham + sham) for 5 days every 6 months until they develop dementia (or MCI for those who are deemed cognitively intact at baseline) or complete the study.

During the COVID-19 pandemic, the study has been modified to be administered in a hybrid manner to accommodate both in-person and virtual assessments. Clinical and cognitive assessments (every 12 months) can be done in person or remotely (via telephone or using WebEx/Zoom). Some assessments are modified to accommodate the change in format of administration while maintaining the validity and integrity of the data. The assessments that cannot be done via phone or videoconference will temporarily not be done.

Similarly, the intervention booster group sessions (every 6 months) can also be provided in two formats of in-person or virtual (via WebEx or Zoom) sessions. The tDCS administration cannot be done remotely and hence the virtual booster sessions will only consist of the CR exercises.

02

Conditions studied

  • Mild Cognitive Impairment
  • Major Depressive Disorder, Recurrent, In Remission
  • Major Depressive Disorder, Single Episode, in Full Remission
03

In context

Cognitive Dysfunction

3,872 studies on the registry are indexed under Cognitive Dysfunction; 1,119 are open to participants now.

This study's enrollment of 375 is above the median of 64 across 2,794 interventional studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

Centre for Addiction and Mental Health is the lead sponsor of 339 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

MCI Group

Inclusion:

  • Age > 60 (on day of randomization)
  • DSM 5 criteria for Mild Neurocognitive Disorder ("MCI")
  • Willingness to provide
  • MADRS score of 10 or below
  • Availability of a study partner who has regular contact with the participant
  • Ability to read and communicate in English (with corrected vision and hearing, if needed)

Exclusion:

  • Met DSM 5 criteria for Major Depressive Episode in past 10 years
  • Lifetime DSM 5 diagnosis of schizophrenia, bipolar disorder, or OCD
  • DSM 5 diagnosis of alcohol or other substances use disorder within the past 12 months
  • High risk for suicide
  • Significant neurological condition (e.g., stroke, seizure disorder, MS)
  • Unstable medical illness, (e.g., uncontrolled diabetes mellitus or hypertension)
  • Having taken a cognitive enhancer (acetylcholinesterase inhibitor or memantine) within the past 6 weeks.
  • Participants taking anticonvulsants, and other psychotropic medication (see exceptions below) that cannot be safely tapered and discontinued. The following psychotropic medications are allowed: i) any antidepressant; ii) zopiclone, trazadone, or a benzodiazepine if they have been taken at a stable dose for at least 4 weeks prior to study entry and; iii) gabapentin and pregabalin if they have been taken at a stable dose for at least 4 weeks prior to study entry AND if prescribed for chronic pain.
  • A pace-maker or other metal implants that would preclude safe use of tDCS.

MDD Group

Inclusion:

  • Age ≥ 65 (on day of randomization)
  • Meets DSM 5 criteria for one or more MDE(s)with:

    1. an offset of 2 months to 5 years from the screening visit date. It is not necessary for this (these) episode(s) to have received medical attention OR
    2. an offset of 5 years or more from the screening visit date. It is necessary that at least one MDE received medical attention (e.g., previously been on one or more antidepressant(s), saw a psychiatrist, primary care physician, or had a previous hospitalization). Also, the MDE must have occurred during the participant's adult life (i.e., at 18 years of age or older).
  • MADRS score of 10 or below
  • Willingness to provide informed consent
  • Availability of a study partner who has regular contact with the participant
  • Ability to read and communicate in English (with corrected vision and hearing, if needed)

Exclusion:

  • Meets DSM 5 criteria for Major Neurocognitive Disorder ("dementia")
  • Lifetime DSM 5 diagnosis of schizophrenia, bipolar disorder, or OCD
  • DSM 5 diagnosis of alcohol or other substances use disorder within the past 12 months.
  • High risk for suicide.
  • Significant neurological condition (e.g., stroke, seizure disorder, MS)
  • Unstable medical illness (e.g., uncontrolled diabetes mellitus or hypertension)
  • Participants taking anticonvulsants, and other psychotropic medication (see exception below) that cannot be safely tapered and discontinued. In addition to any antidepressant, the following psychotropic medications are allowed if they have been taken at a stable dose for at least 4 weeks prior to study entry: zopiclone, trazodone, or a benzodiazepine; and gabapentin or pregabalin if prescribed for chronic pain.
  • Having taken a cognitive enhancer (acetylcholinesterase inhibitor or memantine) within the past 6 weeks.
  • A pace-maker or other metal implants that would preclude safe use of tDCS.
  • Received electroconvulsive therapy (ECT) within 6 months of baseline neruopsychological testing.

Control group

Inclusion:

  • Age > 60
  • MADRS score of 10 or below
  • Willingness to provide informed consent
  • Ability to read and communicate in English (with corrected vision and hearing, if needed)

Exclusion:

  • Meets DSM 5 criteria for Minor or Major Neurocognitive Disorder
  • Any other lifetime DSM 5 diagnosis except for simple/specific phobias
  • Significant neurological condition (e.g., stroke, seizure disorder, MS)
  • Unstable medical illness, (e.g., uncontrolled diabetes mellitus or hypertension)
  • Participants taking anticonvulsants, and other psychotropic medication (see exception below) that cannot be safely tapered and discontinued. The following psychotropic medications are allowed if they have been taken at a stable dose for at least 4 weeks: zopiclone up to 15 mg/day; trazadone up to 150 mg/day; benzodiazepine at a dose of up to 3 mg/day lorazepam-equivalents; gabapentin and pregabalin (if prescribed for pain).
  • A pace-maker or other metal implants
  • Neuropsychological testing within the past 12 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
375 participants (actual)

Study arms

  • Experimental
    tDCS + CR

    Intervention sessions are administered 5 days/week for 8 weeks (induction phase). Then, for 5 days every 6 months (consolidation phase).Transcranial Direct Current Stimulation (tDCS) session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 minutes/session at the beginning of each group session. Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants also complete CR exercises online at home. CR consists of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. "Strategic monitoring and bridging discussions" promotes transfer of cognitive gains to everyday tasks. During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely).

    Other: tDCS + CR

  • Sham comparator
    sham tDCS + sham CR

    First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase). tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session. Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels. During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely).

    Other: sham tDCS + sham CR

Interventions

  • OthertDCS + CR

    First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase). tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 min. at the beginning of each group session. Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. "Strategic monitoring and bridging discussions" will promote transfer of cognitive gains to everyday tasks. During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely).

    Also known as: transcranial Direct Current Stimulation (tDCS), Cognitive Remediation (CR)

  • Othersham tDCS + sham CR

    First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase). tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session. Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels. During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely).

06

What researchers measure

Primary outcomes

  1. Change in cognitive scores over time

    Z-scores for 18 measures of 12 selected cognitive tests will be calculated based on an healthy comparison group; based on these measures, in turn, z-scores will be averaged into six z-scores for six cognitive domains (executive functioning, language, speed of processing, verbal memory, visual memory, and working memory); finally, the six domain z-scores will be averaged into a composite cognitive score, the change of which is the study primary outcome measure that will be used for H1 and H3.

    Time frame: Approximately 4, 12, 24, 36, 48, 60 months after baseline

Secondary outcomes

  1. Percentage of subjects who remain free of MCI or dementia over time

    Based on consensus conference diagnosis made according to DSM-5

    Time frame: Approximately 4, 12, 24, 36, 48, 60 months after baseline

07

Study locations

5 sites
08

References and documents

Publications

  • Song BX, Schecter J, Vieira E, Gallagher D, Diniz BS, Fischer CE, Flint AJ, Herrmann N, Kennedy JL, Mah L, Mulsant B, Pollock BG, Rajji TK, Ma C, Lanctot KL; PACt-MD Study Group. Angiogenesis markers and cognitive response in a randomized trial of cognitive remediation plus transcranial direct current stimulation in older adults at risk of dementia. J Alzheimers Dis. 2026 Jun 16:13872877261457934. doi: 10.1177/13872877261457934. Online ahead of print. PubMed 42300721 ↗
  • Ho NCW, Zhukovsky P, Rajji TK, Bowie CR, Brooks H, Butters MA, Chen Y, Fischer CE, Flint AJ, Herrmann N, Lanctot KL, Lee A, Mah L, Marawi T, Pollock BG, Ryan JD, Schoer N, Ma C, Voineskos AN, Mulsant BH; PACt-MD Study Group. Brain Structures and Cognitive Decline: Moderation Analysis of the PACt-MD Randomized Clinical Trial of Brain Stimulation Plus Cognitive Remediation in Older Adults With Remitted Depression or Mild Cognitive Impairment. Am J Geriatr Psychiatry. 2026 Aug;34(8):1005-1015. doi: 10.1016/j.jagp.2026.04.008. Epub 2026 Apr 30. PubMed 42203570 ↗
  • Rajji TK, Bowie CR, Herrmann N, Pollock BG, Lanctot KL, Kumar S, Flint AJ, Mah L, Fischer CE, Butters MA, Bikson M, Kennedy JL, Blumberger DM, Daskalakis ZJ, Gallagher D, Rapoport MJ, Verhoeff NPLGP, Golas AC, Graff-Guerrero A, Vieira E, Voineskos AN, Brooks H, Melichercik A, Thorpe KE, Mulsant BH; PACt-MD Study Group. Slowing Cognitive Decline in Major Depressive Disorder and Mild Cognitive Impairment: A Randomized Clinical Trial. JAMA Psychiatry. 2025 Jan 1;82(1):12-21. doi: 10.1001/jamapsychiatry.2024.3241. PubMed 39476073 ↗
  • Marawi T, Zhukovsky P, Rashidi-Ranjbar N, Bowie CR, Brooks H, Fischer CE, Flint AJ, Herrmann N, Mah L, Pollock BG, Rajji TK, Tartaglia MC, Voineskos AN, Mulsant BH; PACt-MD Study Group. Brain-Cognition Associations in Older Patients With Remitted Major Depressive Disorder or Mild Cognitive Impairment: A Multivariate Analysis of Gray and White Matter Integrity. Biol Psychiatry. 2023 Dec 15;94(12):913-923. doi: 10.1016/j.biopsych.2023.05.018. Epub 2023 Jun 2. PubMed 37271418 ↗
  • Weinstein AM, Gujral S, Butters MA, Bowie CR, Fischer CE, Flint AJ, Herrmann N, Kennedy JL, Mah L, Ovaysikia S, Pollock BG, Rajji TK, Mulsant BH; PACt-MD Study Group.. Diagnostic Precision in the Detection of Mild Cognitive Impairment: A Comparison of Two Approaches. Am J Geriatr Psychiatry. 2022 Jan;30(1):54-64. doi: 10.1016/j.jagp.2021.04.004. Epub 2021 Apr 14. PubMed 34023224 ↗
  • Chandramouleeshwaran S, Ahsan N, Raymond R, Nobrega JN, Wang W, Fischer CE, Flint AJ, Herrmann N, Kumar S, Lanctot K, Mah L, Mulsant BH, Pollock BG, Rajji TK. Relationships Between a New Cultured Cell-Based Serum Anticholinergic Activity Assay and Anticholinergic Burden Scales or Cognitive Performance in Older Adults. Am J Geriatr Psychiatry. 2021 Dec;29(12):1239-1252. doi: 10.1016/j.jagp.2021.03.002. Epub 2021 Mar 18. PubMed 33846084 ↗
  • Dham P, Bingham KS, Bowie CR, Butters MA, Fischer CE, Flint A, Herrmann N, Kumar S, Mah L, Mulsant BH, Pollock BG, Rajji TK; for PACt-MD Study Group. Functional Competence and Cognition in Individuals With Amnestic Mild Cognitive Impairment. J Am Geriatr Soc. 2020 Aug;68(8):1787-1795. doi: 10.1111/jgs.16454. Epub 2020 Apr 22. PubMed 32323313 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Dec 2022, 95 months.

Of 1,442 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 95 months is above that.

Counting every sponsor, half of 1,511 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2015
First posted
Mar 12, 2015
StartActual
Jan 2015
Primary completionActual
Dec 31, 2022
CompletionEst.
Dec 31, 2026
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02386670
Collaborators
Brain Canada, Applied Health Research Centre, Queen's University, Baycrest Centre for Geriatric Care, Unity Health Toronto, Sunnybrook Health Sciences Centre, University Health Network, Toronto
Responsible party
Benoit Mulsant (Clinician Scientist, Centre for Addiction and Mental Health) — Principal investigator
First posted
Mar 12, 2015
Start date
Jan 2015
Primary completion
Dec 31, 2022
Completion
Dec 31, 2026 (estimated)
Last update
Apr 9, 2026

Study contacts

Benoit H Mulsant, MD
principal investigator · Centre for Addiction and Mental Health

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion